Chlorin e6: Uses in Cancer Treatment and Night Vision

Chlorin e6 is a light-activated compound derived from chlorophyll that has found two strikingly different applications: destroying cancer cells and, in early research, enhancing vision in dim light. In cancer treatment, it serves as a photosensitizer, a molecule that absorbs specific wavelengths of red light and converts that energy into reactive oxygen species that kill tumors from the inside. Its night-vision connection is newer and far less developed, rooted in the discovery that chlorin e6 can interact with rhodopsin, the light-sensing protein in the eye, in ways that shift how the visual system responds to low light. These two uses share a common molecular mechanism but differ enormously in how far they have progressed toward practical application.

How Chlorin e6 Works in Photodynamic Therapy

Photodynamic therapy, or PDT, relies on three ingredients arriving at the same spot at the same time: a photosensitizer, light of the right wavelength, and oxygen already present in tissue. Chlorin e6 is injected into the bloodstream or applied locally, accumulates in the target tissue, and then a clinician shines a laser on the area. The standard activation wavelength is around 660 nanometers, deep in the red part of the visible spectrum, which allows the light to penetrate tissue more deeply than shorter wavelengths would.¹ When the molecule absorbs that light, it transfers energy to nearby oxygen molecules, generating reactive oxygen species. These are chemically aggressive molecules that damage cell membranes, proteins, and DNA within a very small radius of wherever the photosensitizer sits.

What makes chlorin e6 attractive compared to earlier photosensitizers is a combination of practical advantages: it absorbs light strongly at the wavelengths that penetrate tissue best, clears from the body relatively quickly, and causes less lingering skin photosensitivity than first-generation alternatives.² The compound is classified as a second-generation photosensitizer and has received regulatory approval for clinical use.

Why Tumors Absorb More of It

A photosensitizer is only useful for cancer treatment if it ends up in the tumor rather than evenly distributed throughout the body. Chlorin e6 has a built-in advantage here that relates to a basic feature of tumor biology: cancer cells tend to create a slightly acidic environment around themselves. At a pH of about 6.7, which is typical of many tumor microenvironments, chlorin e6 becomes more fat-soluble. That shift in its chemical character means it binds differently to blood proteins and crosses cell membranes more readily. Research has shown that cellular uptake of chlorin e6 is substantially higher at this mildly acidic pH compared to the normal pH of blood and healthy tissue.³

This preferential uptake is one reason PDT can damage tumors while leaving surrounding healthy tissue relatively unharmed. The drug accumulates where it is needed, and the light can be aimed precisely at the tumor site. Together, these two layers of selectivity give clinicians a degree of targeting that systemic chemotherapy drugs often lack.

Three Ways It Kills Cancer Cells

The reactive oxygen species generated by chlorin e6 under light do not kill cancer in just one way. Research has identified at least three distinct mechanisms, and in practice they overlap, which is part of what makes PDT effective.

The most direct pathway is triggering apoptosis, the cell’s own self-destruction program. Studies in mammary tumor models have shown that chlorin e6-mediated therapy ramps up the cell’s death signaling machinery while suppressing the proteins that normally prevent apoptosis.⁴ In essence, the oxidative damage is severe enough that the cell recognizes it cannot repair itself and initiates a controlled shutdown. That same research found significant inhibition of cell migration, suggesting PDT may also slow a tumor’s ability to spread.

The second mechanism targets the tumor’s blood supply. Tumors depend on networks of new blood vessels to feed their growth. When chlorin e6 accumulates in or near those vessels and is activated by light, the resulting damage can collapse the vessels and cut off the tumor’s oxygen and nutrients. In mouse models, researchers tracked blood flow and oxygen saturation in tumors after PDT and found that animals whose tumors shrank by more than 40% in volume showed sharp drops in blood flow and oxygen consumption within hours of treatment.⁵

The third mechanism is immunological, and it is arguably the most interesting for the future of cancer treatment. When chlorin e6-mediated PDT kills cancer cells, it does so in a way that is “immunogenic,” meaning the dying cells release signals that alert the immune system. These include molecules that serve as danger signals, prompting immune cells to recognize the dead tumor cells as threats and mount a broader immune response against any remaining cancer.⁶ In lung cancer cells, researchers found that PDT with chlorin e6 caused oxidative stress in a specific part of the cell, the endoplasmic reticulum, which triggered the translocation of particular immune-signaling molecules to the cell surface. This essentially paints a target on the dying cell for the immune system to see.

Pairing PDT with Immunotherapy

The immune-stimulating effects of chlorin e6-based PDT have prompted researchers to combine it with immunotherapy agents, and the early results are striking. One experimental approach uses nanoparticles loaded with both chlorin e6 and an antibody that blocks CD47, a “don’t eat me” signal that cancer cells display on their surface to avoid being consumed by immune cells. When the nanoparticle reaches the tumor and is activated by light, two things happen simultaneously: the PDT kills cells directly and generates danger signals, while the antibody strips away the tumor’s immune camouflage. The combination accelerates phagocytosis of tumor cells by immune cells and promotes a cascading T-cell response.⁷

Another line of research has taken this further by combining chlorin e6 with checkpoint blockade therapy, the same class of drugs that have transformed treatment for melanoma and certain other cancers. Researchers created a system where chlorin e6 was bound to immunoglobulin molecules, which naturally accumulate in tumors. This allowed them to use the fluorescence of chlorin e6 for real-time imaging during surgery while simultaneously performing PDT and checkpoint blockade. In mouse models of brain and colon cancer, this triple combination of fluorescence-guided surgery, PDT, and dual checkpoint blockade showed promising results.⁸ The broader pattern across these studies is that chlorin e6 may be more valuable as one component in a multi-pronged attack on cancer than as a standalone treatment.⁹

Getting It to the Tumor with Nanocarriers

Chlorin e6 by itself has a few practical limitations. It is not highly soluble in water, which makes intravenous delivery tricky. And while it does preferentially accumulate in tumors thanks to the pH effect described above, that accumulation is not as efficient as researchers would like. This is where nanotechnology enters the picture.

A range of nanoparticle systems have been designed to carry chlorin e6 to tumors more effectively. One approach uses simple nano-precipitation to create tiny chlorin e6 particles with very high drug loading, around 81%, and strong reactive oxygen species generation capability. These nanoparticles showed effectiveness against colorectal cancer cells in laboratory testing.¹⁰ A more sophisticated strategy coats silica nanoparticles carrying chlorin e6 with actual cancer cell membranes. Because the membrane coating comes from gastric cancer cells, the resulting nanoparticle specifically homes in on other gastric cancer cells, both in lab dishes and in living animals.¹¹

Perhaps the most ambitious nanocarrier designs tackle a fundamental weakness of PDT: it needs oxygen to work, but the centers of many tumors are oxygen-starved. One system encapsulates chlorin e6 alongside the chemotherapy drug doxorubicin and manganese dioxide particles inside a polymer shell. The manganese dioxide reacts with hydrogen peroxide in the tumor environment to generate oxygen on-site, essentially bringing its own oxygen supply. This allowed combined chemo-photodynamic therapy in breast cancer models, addressing the hypoxia problem that can limit PDT effectiveness in dense tumors.¹²

Activation by Ultrasound Instead of Light

One of the biggest limitations of PDT is that light cannot penetrate very far into tissue. Even red light at 660 nanometers only reaches a few millimeters deep, which means tumors buried deep in the body are hard to treat with surface-applied light. Sonodynamic therapy, or SDT, offers a potential workaround by using ultrasound waves instead of light to activate the photosensitizer. Ultrasound penetrates tissue far more deeply.

Chlorin e6 turns out to work as a sonosensitizer as well as a photosensitizer. When combined with low-intensity ultrasound, it significantly inhibited the growth of lung adenocarcinoma cells in the lab, even though neither ultrasound alone nor chlorin e6 alone at the tested doses had a meaningful effect.¹³ In living animals, the same pattern held: ultrasound or chlorin e6 given separately produced no substantial antitumor effects, but the combination significantly hampered tumor growth, primarily through inducing cell death.¹⁴

Researchers have also explored combining both ultrasound and light activation together in what is called sono-photodynamic therapy, which produced even stronger effects on tumor cell migration and death than either modality on its own.⁴ SDT remains largely preclinical, but it represents one of the more promising routes to extending the reach of chlorin e6-based treatments to deep-seated cancers that light alone cannot reach.

The Night Vision Connection

The idea that chlorin e6 could enhance night vision emerged from an unexpected direction: studies of deep-sea fish. Certain deep-sea dragonfish species use chlorophyll derivatives, closely related to chlorin e6, in their eyes to see red bioluminescence that their prey cannot detect. This raised the question of whether a similar molecule could alter human visual sensitivity.

The mechanism appears to work through rhodopsin, the light-sensitive protein in the rod cells of the retina that enables vision in dim conditions. Computational and experimental studies have shown that chlorin e6 binds to the intracellular region of rhodopsin and, from that position, remotely influences the protein’s light-sensitive core. Specifically, the binding triggers long-range coordinated movements through the protein structure, affecting the behavior of amino acids in the pocket where retinal, rhodopsin’s light-absorbing component, sits. These changes shift the protein’s spectral sensitivity and alter its thermal stability.¹⁵

More recent work proposed a specific mechanism for how this actually produces enhanced dim-light vision. When chlorin e6 absorbs deep-red light, it generates singlet oxygen, and that singlet oxygen can trigger the isomerization of retinal within rhodopsin, which is the very first step in the visual signaling cascade. This means that chlorin e6 could, in theory, allow rhodopsin to respond to wavelengths of light it would not normally detect, effectively extending the eye’s sensitivity into the near-infrared. The researchers found that previously proposed energy-transfer mechanisms did not hold up, and that the singlet-oxygen pathway was the more credible explanation.¹⁶

It is worth emphasizing that this work is largely molecular and computational. There are no large clinical trials showing that applying chlorin e6 to human eyes safely and reliably improves night vision. A widely reported 2015 amateur experiment by a biohacker group claimed success after dropping a chlorin e6 solution into a volunteer’s eyes, but that experiment lacked controls, blinding, or follow-up safety monitoring. The molecular science is genuinely interesting, but the leap from “this molecule interacts with rhodopsin in ways that could shift spectral sensitivity” to “this can safely give people better night vision” is enormous and largely untraversed by rigorous research.

Safety and Tissue Damage Risks

Because chlorin e6 generates reactive oxygen species by design, the same mechanism that makes it therapeutic also makes it potentially destructive when doses or light exposure are not carefully controlled. This is especially relevant for ocular applications, where the tissue at stake is fragile and irreplaceable.

An experimental study of transscleral PDT with a chlorin e6 formulation in animal eyes mapped out what happens when treatment parameters are pushed beyond safe thresholds. At higher power settings, the damage was severe: retinal necrosis occurred in 35 to 50% of treated eyes depending on the power level, choroidal hemorrhage in 40 to 55%, and structural changes in the sclera in about 30% of cases.¹⁷ The findings underscore that the therapeutic window for ocular use is narrow, and that casual or unsupervised application of chlorin e6 to the eye carries real risks of permanent damage.

For systemic cancer use, the safety profile is more established. Talaporfin sodium, a clinical derivative of chlorin e6, has been studied in patients with skin and mucosal cancers. Photosensitivity, the main side effect of most photosensitizers, resolved within one week of dosing in the vast majority of patients. The drug cleared from the body with a terminal half-life of roughly a week, and it showed rapid systemic clearance compared to first-generation photosensitizers, which could leave patients sensitive to light for weeks.¹⁸

Clinical Derivatives Already in Use

Chlorin e6 itself is a parent molecule that has given rise to several clinical derivatives, the most prominent being talaporfin sodium (also known by its chemical name mono-L-aspartyl chlorin e6, or NPe6). Talaporfin is used clinically in photodynamic therapy and has attracted attention for newer applications including radiodynamic therapy, where it acts as a radiosensitizer rather than a photosensitizer. Its properties include preferential accumulation in tumors, deep tissue penetration, rapid systemic clearance, and minimal photosensitivity compared to older drugs.¹⁹ Talaporfin has been approved for clinical use in Japan for early-stage lung cancer and is being explored in other cancer types and treatment modalities.

The fact that chlorin e6 derivatives can be activated not only by visible light but also by X-rays and ultrasound opens up treatment possibilities for cancers in locations that are difficult to reach with fiber-optic light delivery. This versatility is one of the reasons the compound continues to attract research interest decades after its initial characterization.

Where Chlorin e6 Comes From

Chlorin e6 is not a synthetic creation built from scratch in a lab. It is derived from chlorophyll, the same molecule that makes plants green. The most common production route starts with chlorophyll a extracted from photosynthetic organisms, particularly cyanobacteria like Spirulina. From dry Spirulina biomass, chlorophyll a is extracted and converted through a series of chemical steps into chlorin e6 and its derivatives, with reasonable yields.²⁰ This biological origin is part of what gives the molecule its favorable safety profile: it is structurally similar to molecules the body already encounters through dietary chlorophyll, which may contribute to its relatively rapid metabolism and clearance.

Killing Bacteria with Light

Cancer is not the only medical target for chlorin e6. Antimicrobial photodynamic therapy uses the same reactive oxygen species mechanism to kill bacteria, and it has a particular advantage over antibiotics: bacteria cannot easily develop resistance to being chemically oxidized. Researchers have demonstrated that chlorin e6 combined with light activation kills both free-floating bacteria and bacteria organized into biofilms, which are typically much harder to eliminate. Testing against the three primary bacteria responsible for middle ear infections showed that the treatment achieved at least 99.9% loss of bacterial viability in both planktonic and biofilm forms.²¹

The biofilm result is the more impressive finding. Biofilms are communities of bacteria encased in a protective matrix that shields them from antibiotics and the immune system, and they are a major reason why ear infections recur in children. A treatment that can penetrate and destroy established biofilms could change the management of chronic and recurrent infections, and not just in the ear. Similar approaches are being explored for wound infections, dental infections, and other sites where biofilm-associated bacteria cause persistent disease. The appeal is straightforward: in an era of growing antibiotic resistance, a treatment mechanism that bacteria cannot easily evolve around is inherently valuable.